SBIR Phase I: Biotransformable Block Terpolymers for Drug-Eluting Stents

Award Information
Agency: National Science Foundation
Branch: N/A
Contract: 0712489
Agency Tracking Number: 0712489
Amount: $100,000.00
Phase: Phase I
Program: SBIR
Awards Year: 2007
Solitcitation Year: 2006
Solitcitation Topic Code: BT
Solitcitation Number: NSF 06-598
Small Business Information
Ablitech, Inc.
518 N. Main Street, # 286, Hattiesburg, MS, 39401
Duns: 788730542
Hubzone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Lisa Kemp
 (601) 347-2811
Business Contact
 Lisa Kemp
Title: PhD
Phone: (601) 347-2811
Research Institution
This Small Business Innovation Research (SBIR) Phase I research research project aims to develop a polymer system for drug eluting coronary stents (DES). The material is expected to provide higher drug loading with a controlled drug release profile, as well as tunable mechanical properties over the lifetime of the stent. This will be accomplished using block terpolymers of specific composition to which drug molecules will be covalently attached. Recent advances in DES technology have increased the success rate of CHD treatment; however, restenosis (re-blockage of the artery through the stent) occurs in 10% of the implanted stents. Also currently available drug eluting coatings deliver the bulk of the loaded drug within the first 48 hours of stent placement, with little to no delivery after 30 days. Thus a new type of stent that can overcome the limitations of current stents would be of significant value.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government